RedLabRA, a network of microbiology laboratories, initiated a study to address an increase in vancomycin-resistant enterococci (VRE) within Spanish regions. The project involved two phases: a questionnaire to assess risk perception among Level 2 laboratories and the collection of VRE cases from April 2023 to March 2024. Genomic surveillance, utilizing the Illumina platform, was then applied to a sample of vancomycin-resistant Enterococcus faecium (VREfm) isolates. Analysis included MLST, cgMLST, phylogenetic relationships, and resistome assessment.
Across 12 autonomous communities and the autonomous city Ceuta, 31 Level 2 laboratories reported 1,958 VRE cases originating from 86 hospitals. The primary species identified was E. faecium, representing 97.1% of the cases. Of the 317 VREfm isolates examined, 211 carried the vanA gene, 90 carried the vanB gene, and 16 carried both genes. Several sequence types, including ST117, ST80, and ST1421, were prevalent.
Genomic analysis revealed 45 VREfm clusters, with eight clusters involving at least three hospitals and demonstrating inter-regional connections. Linezolid resistance mechanisms, primarily optrA+cfrD, were found in 51 isolates. The study highlighted an uneven distribution of VREfm across Spanish regions and the presence of genetically similar clones.
Ongoing surveillance is warranted due to the emergence of E. faecium isolates carrying genes conferring resistance to vancomycin and linezolid.